Nuvectis Pharma, Inc. · NASDAQ:NVCT
Nuvectis Pharma — Investor Presentation (March 2024)
25 slides from Nuvectis Pharma's investor presentation, March 2024
Slide 1: Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. Innovative Precision Medicine for Serious Conditions of Unmet Medical Need in Oncology March 2024 (NASDAQ: NVCT)
Slide 2: Forward Looking Statements
Forward Looking Statements Nuvectis Pharma, Inc. Certain statements in this presentation constitute “forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties. All statements, other than statements of historical
Slide 3: Nuvectis Pharma – Key Highlights
Nuvectis Pharma – Key Highlights Our Approach to Select and acquire novel, rationally-designed drug candidates Precision Medicine Focus on drug development for serious conditions of unmet need in oncology Ongoing clinical trials: NXP800 ARID1a-mutated, platinum resistant ovarian carcinoma (F
Slide 4: Management Team
Management Team Track record of success Ron Bentsur Enrique Poradosu, PhD Shay Shemesh Chairman & Chief Executive Officer Chief Scientific & Business Officer Chief Development & Operations Officer Jelmyto® (mitomycin) NuvectisPharma, Inc. 4
Slide 5: Nuvectis Precision Medicine Pipeline
Nuvectis Precision Medicine Pipeline Drug Candidate Indication Phase 1a Phase 1b Phase 2 Phase 3 ARID1a-mutated ovarian cancer Fast Track Designation • Ovarian clear cell carcinoma NXP800 a GCN2 Activator • Ovarian endometrioid carcinoma Cholangiocarcinoma (IST) Orphan Designation Squamous can
Slide 6: About NXP800
4 About NXP800
Slide 7: NXP800 Mechanism of Action
NXP800 Mechanism of Action NXP800 is a GCN2 kinase activator NXP800 NXP800 + A92 (GCN2 inhibitor) NXP800 activates the GCN2 kinase Created with BioRender.com NXP800 (nM) Inhibition of cap-dependent translation and Target validation chronic activation of the integrated stress The GCN2 inhibitor A92
Slide 8: Substantial Antitumor Activity in ARID1a-Mutated Ovarian Carcinoma Xenografts
Substantial Antitumor Activity in ARID1a-Mutated Ovarian Carcinoma Xenografts (NXP800 vs. Cisplatin) Preclinical proof of concept leading to selection of initial target indication SKOV-3 (Cisplatin Resistant) TOV-21G (Cisplatin Sensitive) Est. Total Est. # of Patients Disease Incidence w/ ARID1a (US
Slide 9: Substantial Antitumor Activity in Cholangiocarcinoma
Substantial Antitumor Activity in Cholangiocarcinoma Additional potential development opportunities Cholangiocarcinoma (CCA) is a lethal malignancy with poor prognosis arising from the biliary tree Approx. 10,000 new cases/year in the US a a. The cholangiocarcinoma foundation, cholangiocarcinoma
Slide 10: Potent Antitumor Activity in ARID1a/ARID1b Mutated Endometrial Carcinoma Xenografts
Potent Antitumor Activity in ARID1a/ARID1b Mutated Endometrial Carcinoma Xenografts ARID1a is the most frequently mutated SWI/SNF subunit with an estimated prevalence of 35% in endometrial carcinomas. Inactivation of ARID1b is highly prevalent in undifferentiated and dedifferentiated endometrial
Slide 11: NXP800 Potential Opportunity in Multiple Cancers
NXP800 Potential Opportunity in Multiple Cancers ARID1a is an important mutation that can be used as a patient selection strategy a Estimated Incidence ARID1a mutation Estimated Number of Patients Indication (US) prevalence with ARID1a protein loss (US) Ovarian Cancer 4,350 52.9% 2,300 (Clear Cell a
Slide 12: NXP800: Phase 1b Underway, Fast Track Designation
NXP800: Phase 1b Underway, Fast Track Designation Enrolling patients with platinum-resistant, ARID1a-mutated ovarian cancer (target population) Clinicaltrials.gov NCT05226507 Phase 1a: Dose Escalation - Completed Phase 1b: Dose Expansion - Enrolling Patients with advanced solid tumors (all comers) P
Slide 13: Preliminary Phase 1b Data
Preliminary Phase 1b Data Data reported in two patients treated with 75 mg/day and two treated with 50 mg/day. Prior therapies • All patients failed at least two prior lines of systemic chemotherapy, including at least one prior platinum- based chemotherapy regimen. • Three of the patients also
Slide 14: About NXP900
4 About NXP900
Slide 15: NXP900 Key Highlights
NXP900 Key Highlights Discovered at the University of Edinburgh, Scotland Precision Medicine A potent, novel, small molecule inhibitor of YES1/SRC signaling Approach YES1-Hippo pathway alteration associated with sensitivity to NXP900 in squamous cell models Differentiated Highly selective Fe
Slide 16: NXP900 Kinome Profiling Demonstrates High Selectivity
NXP900 Kinome Profiling Demonstrates High Selectivity NXP900 Dasatinib Note: Dasatinib data from Remsing Rix et al., Leukemia 23, 477–485 (2009), NXP900 data from AACR 2022. NuvectisPharma, Inc. 16
Slide 17: NXP900 Completely Shuts Down Signaling of Non-receptor Tyrosine Kinases of the SRC Family
NXP900 Completely Shuts Down Signaling of Non-receptor Tyrosine Kinases of the SRC Family Differentiated vs. other multi-kinase inhibitors that only achieve a partial SRC pathway shut down NXP900: Complete shutdown of Other multi-kinase inhibitors: Partial No inhibitor: Fully active SRC the SRC path
Slide 18: Targeting YES1 in Cancers of Squamous Cell Origin
Targeting YES1 in Cancers of Squamous Cell Origin Single agent development strategy Genetic alterations in the hippo pathway (FAT1-4, YAP1, TAZ) are highly prevalent in cancers of squamous cell origin and confer sensitivity to NXP900 YES1 drives tumor growth via phosphorylation and nuclear local
Slide 19: Potent Single Agent Activity in Squamous Cell Cancers
Potent Single Agent Activity in Squamous Cell Cancers Esophageal Cancer Head and Neck Cancer (tongue) KYSE70 cells (YES1 gene amplification) Cal27 cells (Heterozygous FAT1 copy loss) NuvectisPharma, Inc. 19
Slide 20: Potential Combination Strategies
Potential Combination Strategies YES1 (in NSCLC) and SRC (in mCRPC) are implicated in development of resistance to osimerinib (Tagrisso) and enzalutamide (Xtandi) NXP900 in combination with enzalutamide overcomes NXP900 in combination with osimertinib overcomes resistance in vitro resistance in vivo
Slide 21: NXP900 Potential Market Opportunity
NXP900 Potential Market Opportunity Squamous cancer cells with hippo pathway alterations and NF2 mutated cells demonstrate high sensitivity to NXP900 in vitro and in vivo Estimated Incidence Estimated Addressable Patient Indication (US) Population (US) Squamous cell prevalence Cervical 13,950 90% 12
Slide 22: NXP900: Phase 1a Ongoing
NXP900: Phase 1a Ongoing Patients with advanced solid tumors Clinicaltrials.gov NCT05873686 Phase 1a Dose Escalation Starting dose of 20 mg, QD Primary Objective: Select doses/schedules for Phase 1b Key Endpoints: Assess Pharmacokinetics, pharmacodynamics, lab abnormalities, dose limiting toxicities
Slide 23: Financial and NVCT Stock Highlights
Financial and NVCT Stock Highlights Cash runway into 1H2025 Financials Insider Ownership Ticker NVCT Founders and >5% holders 66% $19.1M as of Cash 12/31/2023 Research Coverage Joe Pantginis Aydin Huseynov Jonathan Aschoff NuvectisPharma, Inc. 23
Slide 24: Nuvectis Investment Highlights
Nuvectis Investment Highlights Precision medicine pipeline for serious conditions of unmet medical need in oncology Preliminary clinical data for NXP800 (ARID1a-mutated ovarian cancer and cholangiocarcinoma) and 2024 Milestones for NXP900 (Phase 1a study) Presentations at medical and scientific
Slide 25: Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. Innovative Precision Medicine for Serious Conditions of Unmet Medical Need in Oncology March 2024 (NASDAQ: NVCT)